ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 55 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $693,633 | -21.7% | 114,650 | +0.5% | 0.00% | – |
| Q2 2023 | $885,409 | +1067.1% | 114,099 | +757.3% | 0.00% | – |
| Q1 2023 | $75,861 | -3.2% | 13,309 | 0.0% | 0.00% | – |
| Q4 2022 | $78,390 | +82.3% | 13,309 | 0.0% | 0.00% | – |
| Q3 2022 | $43,000 | -28.3% | 13,309 | 0.0% | 0.00% | – |
| Q2 2022 | $60,000 | -89.8% | 13,309 | -87.9% | 0.00% | – |
| Q1 2022 | $590,000 | -64.4% | 110,440 | -2.0% | 0.00% | – |
| Q4 2021 | $1,656,000 | -28.5% | 112,689 | +1.7% | 0.00% | – |
| Q3 2021 | $2,317,000 | +60.0% | 110,814 | +35.4% | 0.00% | – |
| Q2 2021 | $1,448,000 | -23.0% | 81,819 | +6.6% | 0.00% | – |
| Q1 2021 | $1,881,000 | -24.6% | 76,787 | +4.1% | 0.00% | -100.0% |
| Q4 2020 | $2,496,000 | +342.6% | 73,731 | +226.5% | 0.00% | – |
| Q3 2020 | $564,000 | -26.4% | 22,584 | -0.5% | 0.00% | – |
| Q2 2020 | $766,000 | – | 22,706 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,007,576 | $25,199,000 | 12.12% |
| Svennilson Peter | 4,768,181 | $119,252,000 | 9.73% |
| EcoR1 Capital, LLC | 2,642,218 | $66,082,000 | 4.71% |
| Orbimed Advisors | 2,921,967 | $73,078,000 | 0.92% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 312,483 | $7,815,000 | 0.35% |
| EMERALD ADVISERS, LLC | 324,582 | $8,118,000 | 0.33% |
| Casdin Capital, LLC | 251,515 | $6,290,000 | 0.28% |
| ArrowMark Colorado Holdings LLC | 995,382 | $24,895,000 | 0.24% |
| Artal Group S.A. | 142,500 | $3,564,000 | 0.09% |
| Alyeska Investment Group, L.P. | 161,585 | $4,041,000 | 0.06% |